Management of bladder, prostatic and pelvic floor disorders

Neurotoxicity Research

Volumn 9, Issue 2-3, 2006, Pages 161-172

  Brisinda, Giuseppe ^a   Maria, Giorgio ^a   Bentivoglio, Anna Rita ^a   Cadeddu, Federica ^a   Marniga, Gaia ^a   Brandara, Francesco ^a   Albanese, Alberto ^b  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b UNIVERSITÀ CATTOLICA DEL SACRO CUORE   (Italy)

Author keywords

Anus; Autonomic nervous system diseases; Benign prostatic hyperplasia; Botulinum toxin; Constipation; Detrusor sphincter dyssynergia; Fissure in ano; Gastrointestinal motility; Overactive bladder; Pelvic floor; Prostate; Urinary retention

Indexed keywords

BOTULINUM TOXIN;

ANIMAL; BLADDER DISEASE; HUMAN; MALE; NEUROMUSCULAR DISEASE; PELVIS FLOOR; PROSTATE DISEASE; RECTUM DISEASE; REVIEW; URINARY TRACT DISEASE;

ANIMALS; BOTULINUM TOXINS; HUMANS; MALE; NEUROMUSCULAR DISEASES; PELVIC FLOOR; PROSTATIC DISEASES; RECTAL DISEASES; URINARY BLADDER DISEASES; UROLOGIC DISEASES;

EID: 33747173092     PISSN: 10298428     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03033935     Document Type: Review

References (94)

1. Albanese A, G Maria, AR Bentivoglio, G Brisinda, E Cassetta and P Tonali (1997) Severe constipation in Parkinson's disease relieved by botulinum toxin. Mov. Disord. 12, 764-766.
2. Albanese A, G Brisinda and CJ Mathias (2001) The autonomic nervous system and gastrointestinal disorders, In The Autonomic Nervous System. Part II. Dysfunctions (Appenzeller O, Ed.) (Elsevier:AMsterdam), pp 613-663.
3. Albanese A, G Brisinda, AR Bentivoglio and G Maria (2003) Treatment of outlet obstruction constipation in Parkinson's disease with botulinum neurotoxin A. Am. J. Gastroenterol. 98, 1439-1440.
4. Bagi P and F Biering-Sorensen (2004) Botulinum toxin A for treatment of neurogenic detrussor overactivity and incontinence in patients with spinal cord lesions. Scand. J. Urol. Nephrol. 38, 495-498.
5. Barry MJ and CG Roehrborn (2001) Benign prostatic hyperplasia. BMJ 323, 1042-1046.
6. Barry MJ, FJ Fowler Jr, MP O'Leary, RC Bruskewitz, HL Holtgrewe and WK Mebust (1992a) Correlation of the American Urological Association symptom index with self-administered versions of the Madsen-Iversen, Boyarsky and Maine Medical Assessment Program symptom indexes. Measurement Committee of the American Urological Association. J. Urol. 148, 1558-1563.
7. Barry MJ, FJ Fowler Jr, MP O'Leary, RC Bruskewitz, HL Holtgrewe, WK Mebust and AT Cockett (1992b) The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J. Urol. 148, 1549-1557.
8. Barry MJ, CJ Girman, MP O'Leary, ES Walker-Corkery, BS Binkowitz, AT Cockett and HA Guess (1995) Using repeated measures of symptom score, uroflowmetry and prostate specific antigen in the clinical management of prostate disease. Benign Prostatic Hyperplasia Treatment Outcomes Study Group. J. Urol. 153, 99-103.
9. Beleggia F, E Beccia, E Imbriani, M Basciani, D Intiso, R Cioffi, P Simone and B Ricci (1997) [The use of type A botulin toxin in the treatment of detrusor-sphincter dyssynergia]. Arch. Ital. Urol. Androl. 69 Suppl. 1, 61-63.
10. Boyle P, C Robertson, R Manski, RJ Padley and CG Roehrborn (2001) Meta-analysis of randomized trials of terazosin in the treatment of benign prostatic hyperplasia. Urology 58, 717-722.
11. Brisinda G, G Maria, AR Bentivoglio, E Cassetta, D Gui and A Albanese (1999) A comparison of injections of botulinum toxin and topical nitroglycerin ointment for the treatment of chronic anal fissure. New Engl. J. Med. 341, 65-69.
12. Brisinda G, G Maria and A Albanese (2002a) Anisme, fissure anale, In Manuel d'utilisation pratique de la toxine botulique (Ranoux D and C Gury, Eds.) (Marseille, Solal, editeur: Marseille), pp 201-217.
13. Brisinda G, G Maria, AR Bentivoglio and A Albanese (2002b) The role of botulinum toxin in gastrointestinal disorders, In Scientific and Therapeutic Aspects of Botulinum Toxin (Brin MF, M Hallett and J Jankovic, Eds.) (Lippincott Williams & Wilkins: Philadelphia), pp 269-285.
14. Brisinda D, G Maria, R Fenici, IM Civello and G Brisinda (2003a) Safety of botulinum neurotoxin treatment in patients with chronic anal fissure. Dis. Colon Rectum 46, 419-420.
15. Brisinda G, IM Civello, A Albanese and G Maria (2003b) Gastrointestinal smooth muscles and sphincters spasms: Treatment with botulinum neurotoxin. Curr. Med. Chem. 10, 603-623.
16. Brown AC, JM Sumfest and JV Rozwadowski (1989) Histopathology of the internal anal sphincter in chronic anal fissure. Dis. Colon Rectum 32, 680-683.
17. Christiansen J, E Bruune, B Skjoldbye and K Hagen (2001) Chronic idiopathic anal pain. Dis. Colon Rectum 44, 661-665.
18. Chuang YC, PH Chiang, CC Huang, N Yoshimura and MB Chancellor (2005) Botulinum toxin type A improves benign prostatic hyperplasia symptoms in patients with small prostates. Urology 66, 775-779.
19. Clifford GM and RD Farmer (2000) Medical therapy for benign prostatic hyperplasia: A review of the literature. Eur. Urol. 38, 2-19.
20. Davies J, D Duffy, N Boyt, A Aghahoseini, D Alexander and S Leveson (2003) Botulinum toxin (botox) reduces pain after hem-orrhoidectomy: results of a double-blind, randomized study. Dis. Colon Rectum 46, 1097-1102.
21. de la Rosette JJ, G Alivizatos, S Madersbacher, M Perachino, D Thomas, F Desgrandchamps and M de Wildt (2001) EAU Guidelines on benign prostatic hyperplasia (BPH). Eur. Urol. 40, 256-263.
22. de Seze M, H Petit, P Gallien, MP de Seze, PA Joseph, JM Mazaux and M Barat (2002) Botulinum A toxin and detrusor sphincter dyssynergia: A double-blind lidocaine-controlled study in 13 patients with spinal cord disease. Eur. Urol. 42, 56-62.
23. Djavan B, S Madersbacher, HC Klingler, K Ghawidel, A Basharkhah, S Hruby, C Seitz and M Marberger (1999) Outcome analysis of minimally invasive treatments for benign prostatic hyperplasia. Tech. Urol. 5, 12-20.
24. Doehring CB, MG Sanda, AW Partin, J Sauvageot, H Juo, TH Beaty, JI Epstein, G Hill and PC Walsh (1996) Histopathologic characterization of hereditary benign prostatic hyperplasia. Urology 48, 650-653.
25. Doggweiler R, DH Zermann, M Ishigooka and RA Schmidt (1998) Botox-induced prostatic involution. Prostate 37, 44-50.
26. Dykstra DD and AA Sidi (1990) Treatment of detrussor-sphincter dyssynergia with botulinum A toxin: A double-blind study. Arch. Phys. Med. Rehabil. 71, 24-26.
27. Dykstra DD, AA Sidi, AB Scott, JM Pagel and GD Goldish (1988) Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients. J. Urol. 139, 919-922.
28. Farnsworth WE (1999) Prostate stroma: Physiology. Prostate 38, 60-72.
29. Dykstra D, A Enriquez and M Valley (2003) Treatment of over-active bladder with botulinum toxin type B: A pilot study. Int. Urogynecol. J. Pelvic Floor Dysfunct. 14, 424-426.
30. Gallien P, S Robineau, M Verin, MP Le Bot, B Nicolas and R Brissot (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch. Phys. Med. Rehabil. 79, 715-717.
31. Giannantoni A, SM Di Stasi, RL Stephen, V Bin, E Costantini and M Porena (2004) Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: A prospective randomized study. J. Urol. 172(1), 240-243.
32. Gup DI, E Shapiro, M Baumann and H Lepor (1990) Autonomic receptors in human prostate adenomas. J. Urol. 143, 179-185.
33. Hallan RI, NS Williams, J Melling, DJ Waldron, NR Womack and JF Morrison (1988) Treatment of anismus in intractable constipation with botulinum A toxin. Lancet 2, 714-717.
34. Hollander JB and AC Diokno (1996) Prostatism: Benign prostatic hyperplasia. Urol. Clin. North Am. 23, 75-86.
35. Joo JS, F Agachan, B Wolff, JJ Nogueras and SD Wexner (1996) Initial North American experience with botulinum toxin type A for treatment of anismus. Dis. Colon Rectum 39, 1107-1111.
36. Kaplan SA, HL Holtgrewe, R Bruskewitz, B Saltzman, D Mobley, P Narayan, RH Lund, S Weiner, G Wells, TJ Cook, A Meehan and J Waldstreicher (2001) Comparison of the efficacy and safety of finasteride in older versus younger men with benign prostatic hyperplasia. Urology 57, 1073-1077.
37. Kuo HC (2003) Botulinum A toxin urethral injection for the treatment of lower urinary tract dysfunction. J. Urol. 170, 1908-1912.
38. Langer JC and E Birnbaum (1997) Preliminary experience with intrasphincteric botulinum toxin for persistent constipation after pull-through for Hirschsprung's disease. J. Pediatr. Surg. 32, 1059-1061.
39. Leippold T, A Reitz and B Schurch (2003) Botulinum toxin as a new therapy option for voiding disorders: Current state of the art. Eur. Urol. 44, 165-174.
40. Lepor H (1990) Role of long-acting selective alpha-1 blockers in the treatment of benign prostatic hyperplasia. Urol. Clin. North Am. 17, 651-659.
41. Lepor H, WO Williford, MJ Barry, MK Brawer, CM Dixon, G Gormley, C Haakenson, M Machi, P Narayan and RJ Padley (1996) The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group. New Engl. J. Med. 335, 533-539.
42. Lu-Yao GL, MJ Barry, CH Chang, JH Wasson and JE Wennberg (1994) Transurethral resection of the prostate among Medicare beneficiaries in the United States: Time trends and outcomes. Prostate Patient Outcomes Research Team (PORT). Urology 44, 692-698.
43. Lund JN, C Binch, J McGrath, RA Sparrow and JH Scholefield (1999) Topographical distribution of blood supply to the anal canal. Br. J. Surg. 86, 496-498.
44. Madoff RD and JW Fleshman (2003) AGA technical review on the diagnosis and care of patients with anal fissure. Gastroenterology 124, 235-245.
45. Mall V, FX Glocker, A Frankenschmidt, N Gordjani, F Heinen, M Brandis and R Korinthenberg (2001) Treatment of neuropathic bladder using botulinum toxin A in a 1-year-old child with myelomeningocele. Pediatr. Nephrol. 16(12), 1161-1162.
46. Maria G, G Brisinda, AR Bentivoglio, E Cassetta, D Gui and A Albanese (1998a) Botulinum toxin injections in the internal anal sphincter for the treatment of chronic anal fissure: Long-term results after two different dosage regimens. Ann. Surg. 228, 664-669.
47. Maria G, E Cassetta, D Gui, G Brisinda, AR Bentivoglio and A Albanese (1998b) A comparison of botulinum toxin and saline for the treatment of chronic anal fissure. New Engl. J. Med. 338, 217-220.
48. Maria G, A Destito, S Lacquaniti, AR Bentivoglio, G Brisinda and A Albanese (1998c) Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 352, 625.
49. Maria G, G Brisinda, AR Bentivoglio, E Cassetta and A Albanese (2000a) Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis. Colon Rectum 43, 376-380.
50. Maria G, G Brisinda, AR Bentivoglio, E Cassetta, D Gui and A Albanese (2000b) Influence of botulinum toxin site of injections on healing rate in patients with chronic anal fissure. Am. J. Surg. 179, 46-50.
51. Maria G, G Brisinda, AR Bentivoglio, A Albanese, G Sganga and M Castagneto (2001) Anterior rectocele due to obstructed defecation relieved by botulinum toxin. Surgery 129, 524-529.
52. Maria, G, G Brisinda, I M Civello, AR Bentivoglio, G Sganga and A Albanese (2003) Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: Results of a randomized, placebo-controlled study. Urology 62, 259-264.
53. Mathers SE, PA Kempster, M Swash and AJ Lees (1988) Constipation and paradoxical puborectalis contraction in anismus and Parkinson's disease: a dystonic phenomenon? J. Neurol. Neurosurg. Psychiatry 51, 1503-1507.
54. Mathias CJ and R Bannister (1999) Investigation of autonomic disorders, In Autonomic Failure. A Textbook of Clinical Disorders of the Autonomic Nervous System (Mathias CJ and R Bannister, Eds.) (Oxford University Press:NEw York), pp 169-195.
55. McCallion K and KR Gardiner (2001) Progress in the understanding and treatment of chronic anal fissure. Postgrad. Med. J. 77, 753-758.
56. McConnell JD, MJ Barry and RC Bruskewitz (1994) Benign prostatic hyperplasia: Diagnosis and treatment. Agency for Health Care Policy and Research. Clin. Pract. Guidel Quick Ref. Guide Clin. pp. 1-17.
57. McConnell JD, R Bruskewitz, P Walsh, G Andriole, M Lieber, HL Holtgrewe, P Albertsen, CG Roehrborn, JC Nickel, DZ Wang, AM Taylor and J Waldstreicher (1998) The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. New Engl. J. Med, 338, 557-563.
58. McVary KT, KE McKenna and C Lee (1998) Prostate innervation. Prostate Suppl. 8, 2-13.
59. Minguez M, B Herreros, A Espi, E Garcia-Granero, V Sanchiz, F Mora, S Lledo and A Benages (2002) Long-term follow-up (42 months) of chronic anal fissure after healing with botulinum toxin. Gastroenterology 123, 112-117.
60. Minguez M, B Herreros and A Benages (2003) Chronic anal fissure. Curr. Treat. Options Gastroenterol. 6, 257-262.
61. Minkes RK and JC Langer (2000) A prospective study of botulinum toxin for internal anal sphincter hypertonicity in children with Hirschsprung's disease. J. Pediatr. Surg. 35, 1733-1736.
62. Morris JL, P Jobling and IL Gibbins (2001) Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am. J. Physiol. Heart Circ. Physiol. 281, H2124-H2132.
63. Narayan P and H Lepor (2001) Long-term, open-label, phase III multi-center study of tamsulosin in benign prostatic hyperplasia. Urology 57, 466-470.
64. Nelson RL (2003) Treatment of anal fissure. BMJ 327, 354-355.
65. Nelson RL (2004) Non surgical therapy for anal fissure. The Cochrane Database of systematic Reviews. Volume 4.
66. Oesterling JE (1995) Benign prostatic hyperplasia. Medical and minimally invasive treatment options. New Engl. J. Med. 332, 99-109.
67. Parratte B, V Bonniaud, L Tatu, G Metton, F Michel, A Cosson and G Monnier (2003) [Detrusor-sphincter dyssynergia and botulinum toxin]. Ann. Readapt. Med. Phys. 46, 319-325.
68. Petit H, L Wiart, E Gaujard, F Le Breton, JM Ferriere, A Lagueny, PA Joseph and M Barat (1998) Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease. Spinal Cord 36, 91-94.
69. Phelan MW, M Franks, GT Somogyi, T Yokoyama, MO Fraser, JP Lavelle, N Yoshimura and MB Chancellor (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J. Urol. 165, 1107-1110.
70. Pistolesi D, C Selli, B Rossi and G Stampacchia (2004) Botulinum toxin type B for type A resistant bladder spasticity. J. Urol. 171, 802-803.
71. Radziszewski P and A Borkowski (2003) Botulinum toxin type A intravesical injections for intractable bladder overactivity. Eur. Urol. Suppl. 2(1), 134.
72. Rapp DE, A Lucioni, EE Katz, RC O'Connor, GS Gerber and GT Bales (2004) Use of botulinum-A toxin for the treatment of refractory overactive bladder symptoms: An initial experience. Urology 63(6), 1071-1075.
73. Reitz A, M Stohrer, G Kramer, G Del Popolo, E Chartier-Kastler, J Panneck, H Burgdorfer, K Gocking, H Madersbacher, S Schumacher, R Richter, J Von Tobel and B Schurch (2003) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. Eur. Urol. Suppl. 2(1), 140.
74. Riccabona M, M Koen, M Schindler, B Goedele, A Pycha, L Lusuardi and SB Bauer (2004) Botulinum-A toxin injection into the detrusor: A safe alternative in the treatment of children with myelomeningo-cele with detrusor hyperreflexia. J. Urol. 171(2), 845-848.
75. Roehrborn, CG, G Bartsch, R Kirby, G Andriole, P Boyle, RJ de la, P Perrin, E Ramsey, J Nordling, FG De Campos and S Arap (2001) Guidelines for the diagnosis and treatment of benign prostatic hyperplasia: A comparative, international overview. Urology 58, 642-650.
76. Ron Y, Y Avni, A Lukovetski, J Wardi, D Geva, S Birkenfeld and Z Halpern (2001) Botulinum toxin type-A in therapy of patients with anismus. Dis. Colon Rectum 44, 1821-1826.
77. Ruggieri MR, MD Colton, P Wang, J Wang, RJ Smyth, MA Pontari and GR Luthin (1995) Human prostate muscarinic receptor subtypes. J. Pharmacol. Exp. Ther. 274, 976-982.
78. Sailer M, D Bussen, ES Debus, KH Fuchs and A Thiede (1998) Quality of life in patients with benign anorectal disorders. Br. J. Surg. 85, 1716-1719.
79. Schouten WR, JW Briel, JJ Auwerda and EJ De Graaf (1996) Ischaemic nature of anal fissure. Br. J. Surg. 83, 63-65.
80. Schulte-Baukloh H, HH Knispel and T Michael (2002a) Botulinum-A toxin in the treatment of neurogenic bladder in children. Pediatrics 110, 420-421.
81. Schulte-Baukloh H, T Michael, J Schobert, T Stolze and HH Knispel (2002b) Efficacy of botulinum-A toxin in children with detrusor hyperreflexia due to myelomeningocele: Preliminary results. Urology 59, 325-327.
82. Schulte-Baukloh H, T Michael, B Sturzebecher and HH Knispel (2003) Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder. Eur. Urol. 44, 139-143.
83. Schulte-Baukloh H, C Weiss, T Stolze, B Sturzebecher and HH Knispel (2005) Botulinum-A toxin for treatment of overactive bladder without detrusor overactivity: Urodynamic outcome and patient satisfaction. Urology 66, 82-87.
84. Schurch B (1998) Botulinum A toxin in spinal cord injury. Arch. Phys. Med. Rehabil. 79, 1481.
85. Schurch B, J Hodler and B Rodic (1997) Botulinum A toxin as a treatment of detrusor-sphincter dyssynergia in patients with spinal cord injury: MRI controlled transperineal injections. J. Neurol. Neurosurg. Psychiatry 63, 474-476.
86. Schurch B, DM Schmid and M Stohrer (2000a) Treatment of neurogenic incontinence with botulinum toxin A. N. Engl. J. Med. 342, 665.
87. Schurch B, M Stohrer, G Kramer, DM Schmid, G Gaul and D Hauri (2000b) Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results. J. Urol. 164, 692-697.
88. Schurch B, M de Seze, P Denys, E Chartier-Kastler, F Haab, K Everaert, P Plante, B Perrouin-Verbe, C Kumar, S Fraczek and MF Brin (2005) Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study. J. Urol. 174, 196-200.
89. Shafik A and O El Sibai (1998) Botulin toxin in the treatment of nonre-laxing puborectalis syndrome. Dig. Surg. 15, 347-351.
90. Smith CP, P Radziszewski, A Borkowski, GT Somogyi, TB Boone and MB Chancellor (2004) Botulinum toxin a has antinociceptive effects in treating interstitial cystitis. Urology 64, 871-875.
91. Staehler M, T Sauter and K Miller (2003) Long term results proof botulinum toxin A injection in the m. detrusor vesicae to be an alternative to surgery in childrens with myelomeningocele. Eur. Urol. Suppl. 2(1), 140.
92. Tilney HS, AG Heriot and NP Cripps (2001) Complication of botulinum toxin injections for anal fissure. Dis. Colon Rectum 44, 1721-1724.
93. Walsh PC (1996) Treatment of benign prostatic hyperplasia. New Engl. J. Med. 335, 586-587.
94. Zermann D, M Ishigooka, J Schubert and RA Schmidt (2000) Perisphincteric injection of botulinum toxin type A. A treatment option for patients with chronic prostatic pain? Eur. Urol. 38, 393-399.